Rapamycin has favorable effects on aging in mice and may eventually be applied to encourage "healthy aging" in humans. This study analyzed raw data from 29 survival studies of rapamycin-and control-treated mice, with the goals of estimating summary statistics and identifying factors associated with effect size heterogeneity. Meta-analysis demonstrated significant heterogeneity across studies, with hazard ratio (HR) estimates ranging from 0.22 (95% confidence interval [CI]: 0.06-0.82) to 0.92 (95% CI: 0.65-1.28). Sex was the major factor accounting for effect size variation, and mortality was decreased more in females (HR = 0.41; 95% CI: 0.35-0.48) as compared with males (HR = 0.63; 95% CI: 0.55-0.71). Rapamycin effects were also genotype dependent, however, with stronger survivorship increases in hybrid mice (14.4%; 95% CI: 12.5-16.3%) relative to pure inbred strains (8.8%; 95% CI: 6.2-11.6%). Number needed to treat was applied as an effect size metric, which consistently identified early senescence as the age of peak treatment benefit. These results provide synthesis of existing data to support the potential translation of findings from mouse to primate species. Because rapamycin's effect on survival depends on sex and genotype, further work is justified to understand how these factors shape treatment response.
Mouse survivorship experiments serve as guideposts in aging research and have traditionally been weighed heavily in determining which treatments or genetic mutations represent promising targets for investigation. This is the rationale underlying the National Institute on Aging (NIA) Intervention Testing program (ITP), for instance, which tests compounds to determine whether they have a significant impact on the life span of genetically heterogeneous mice (1) . The main goal of ITP is to provide foundational data that are robust, with survivorship experiments replicated at three independent locations, utilizing hybrid mice generated by crossing four inbred strains (BALB/cByJ, C57BL/6J, C3H/HeJ, and DBA/2J) (1) . This has so far identified several compounds with positive effects on mouse life span (eg, rapamycin, aspirin, and nordihydroguaiaretic acid), along with others that lack such effects (eg, resveratrol and simvastatin) (2) (3) (4) (5) (6) . Of the former, rapamycin has emerged as a leading prolongevity pharmaceutical candidate (2) , and numerous studies of rapamycin's effect on aging outcomes have been motivated by ITP survivorship data (7) . These studies have provided mechanistic insights and shown that, to some degree, both health span and life span can be improved by rapamycin treatment in mice (8) . This has stimulated interest in the translation potential of rapamycin, and rapamycin-related compounds (ie, rapalogs), with the hope that such compounds will eventually prove useful in humans to prevent or delay age-related disease (9, 10) .
The effects of rapamycin on mouse life span have now been reevaluated by independent laboratories utilizing different protocols and mouse genotypes (11) (12) (13) (14) (15) (16) . These studies have mostly demonstrated favorable effects of rapamycin on mouse life span, but findings have not been entirely consistent and estimated survivorship effect sizes have varied (11) (12) (13) (14) (15) (16) . This variation may be attributable to a range of sources recognized as influential in mouse survivorship assays, including sex, genotype, rapamycin dose, age of treatment onset, housing conditions, and/or diet (17) . For rapamycin treatment, compelling evidence indicates that sex significantly impacts the rapamycin treatment effect, with stronger longevity increases in female as compared with male mice (6, 18) . In one study utilizing inbred mice, however, only a small sex difference was observed with nonsignificant sex-by-treatment interaction (14) . A recent study, moreover, has complicated the picture, by demonstrating that rapamycin treatment initiated at 4 months of age decreased life span of db/db diabetic mice in both sexes (C57BL/KsJ background) (15) . This is likely due to deleterious effects of rapamycin on glucose homeostasis, which is unbalanced in db/db mice as evidenced by hyperglycemia and hyperinsulinemia (15) . Recent data have also suggested mechanisms by which mTORC1 inhibition improves the ability of cells to utilize extracellular proteins as an energy source, potentially facilitating tumor growth or metastasis (19) . These findings suggest that effects of rapamycin may be influenced by sex or unique characteristics of mouse strains, which vary with regard to glucose parameters (20) and their propensity to develop different forms of cancer (21) .
Meta-analysis provides a toolkit for data synthesis and can help resolve conflicting evidence from mouse survivorship studies (18, 22) . In this context, meta-analysis can be used to estimate summary treatment effects incorporating all available survivorship data (ie, metaestimates), quantify uncertainty associated with these effects (ie, confidence intervals [CIs]), identify factors associated with outcome heterogeneity, identify outlier experiments, and address the possibility of publication bias (22) . Meta-analysis also provides the opportunity to compare outcomes across studies using more than one statistical approach. This is important considering that mouse survivorship data can be analyzed in multiple ways (23) , and each approach may not be equally meaningful to different audiences (eg, biostatisticians, biologists, and clinicians). Biostatisticians or epidemiologists, for example, may have an intuitive feel for hazard ratios and favor Cox regression models (eg, the proportional hazards [PH] model) (23, 24) . Aging biologists, in contrast, often focus on survival curves and may favor models for which coefficient estimates relate directly to survivorship, rather than the hazard function (eg, accelerated failure time [AFT] models) (23, 25) . Finally, clinicians may disfavor relative statistics, such as hazard ratios, because such measures can be misleading with regard to the clinical significance of a treatment (26, 27) . Clinical significance, in contrast, may relate more reliably to absolute survivorship differences, which reflect the number of patients requiring treatment to generate one additional survivor at a given age (ie, number needed to treat, NNT) (26, 27) .
This study provides a meta-analysis of laboratory experiments that have evaluated the effect of rapamycin on life span in the laboratory mouse. The analysis incorporates data from 29 independent experiments, where each experiment contributes survival times from two mouse cohorts (rapamycin-vs non-treated). All analyses are performed starting with raw data (ie, individual survival times). Treatment effects are estimated using multiple metrics, including the hazard ratio (HR) (24) , AFT model deceleration factor (ie, percent survivorship increase/decrease) (25) , and NNT (26) . These approaches encompass a broader range of statistical methods than has previously been applied to quantify effects of rapamycin on mouse life span. Utilizing these methods, goals of this study were to quantify the magnitude and variation of rapamycin treatment effects and to determine which factors contribute most to effect size heterogeneity.
Methods

Literature Review to Identify Rapamycin Experiments
A literature review was performed to identify randomized controlled experiments evaluating the effects of rapamycin treatment on survival in the laboratory mouse (Supplementary Tables S1 and S2 ). In this context, "experiment" refers to a comparison between two treatment groups, with an experimental group receiving rapamycin and control group receiving no treatment (or placebo). The initial review identified 85 experiments meeting these criteria, of which 56 were excluded from the meta-analysis (Supplementary Table S2 , and Apc ∆716 mice). In such mice, the effects of rapamycin on survival are difficult to interpret and may involve mechanisms distinct from those at work in "normal" or wild type (WT) mice. Other experiments were excluded because they evaluated short-lived obese mice that had received a 60% fat diet (28) , because rapamycin was co-administered with other drugs (29) , or because rapamycin was administered for only 6 weeks (30) (Supplementary Table S2 ). 12 excluded experiments were generated from studies involving one control group and three experimental groups provided a low (4.7 ppm), middle (14 ppm), or high (42 ppm) rapamycin dose (6) . For such experiments, it wasn't possible to estimate effects of rapamycin independently with respect to each of the three dosing levels (due to the shared control group). To avoid nonindependence of treatment effect estimates, therefore, 12 experiments utilizing the low or high dose were excluded (those utilizing the middle 14-ppm dose were included) (6) .
Following these filtering steps, there remained 29 experiments upon which the meta-analysis was based, where each experiment had been performed independently (Supplementary Table S1 ). Most experiments (27/29) administered encapsulated rapamycin at the same dose (14 ppm), or otherwise (2/29), the drug was given by subcutaneous (1.5 mg/kg; 6 times per month) or intraperitoneal (2 mg/ kg; 6 times per month) injection (11, 16) .
Raw Survival Time Data Sets
Meta-analysis can be performed using treatment effect estimates reported in research publications, but this is challenging because studies differ with regard to statistical methods and often do not report all required information (eg, standard errors or 95% CIs) (31) . Analyses were therefore performed using raw survival times, which allowed treatment effects to be consistently estimated across studies using the same statistical methodology.
For 19 of 29 experiments, raw survival times were obtained from the SurvCurv database (32) or from published supplementary material (16) . For the remaining 10 experiments, raw survival times were estimated by image analysis of survival curves from original research publications (31) . These analyses were performed using the DigitizeIt analysis software (http://www.digitizeit.de/). This software uses labeled axes from the published survival curve to define a coordinate system, which is then used to estimate the location of points (or lines) comprising each survival curve, yielding an estimate of the survival function. Given the number of mice initially assigned to each group (reported in publications), the decay in survival over time can be used to estimate raw survival times (31) . Using this approach, it was usually possible to generate effect size estimates in good agreement with those reported by research publications, with the exception of one experiment (12) for which reported and estimated p values differed slightly (p = .032 reported; p = .128 calculated from estimated survival times; Supplementary Table  S3) . Survival times used to perform analyses were utilized to generate survival curves, which are included as Supplementary Material for each of the 29 experiments (Supplementary Figure S1 ).
Cox PH Model
The Cox PH regression model was fit for each experiment using a single 0-1 covariate that designated whether mice belonged to the rapamycin (covariate = 1) or control (covariate = 0) treatment (R package: survival; function: coxph) (23,24). Censoring information was available for 19 of 29 experiments and incorporated into models. Quality of model fits was assessed using log-log plots, residual analysis (Cox-Snell, Martingale, Schoenfeld and deviance residuals), and metrics to identify influential or outlying observations (eg, df-betas) (23) . Log-log plots and Schoenfeld residual analysis were used to assess the PH assumption (Supplementary  Figure S2 and Supplementary Table S4) . Validity of this assumption may be suspect, given that rapamycin treatment was initiated at a late age in some experiments (eg, 20 months). However, log-log plots usually did not reveal strong Treatment × Age interaction (Supplementary Figure S2) , and likewise, scaled Schoenfeld residuals showed a significant time trend in only one experiment (Supplementary Table S4 ; R package: survival; function: cox.zph). Hazards were most likely proportional because most survival times were greater than the age at which rapamycin treatment was initiated. One approach to addressing nonproportional hazards was to include an additional 0-1 covariate for each model (ie, heaviside function) to indicate whether a survival time occurred before (value = 0) or after (value = 1) the onset of rapamycin treatment (23) . This had little impact on the results, however, with HR estimates differing only by 0.014 (±0.007) on average. Analyses were thus based on univariate Cox PH models without additional covariates to account for treatment-by-age interaction. Diagnostic plots indicated that univariate models provided adequate fit for most or all experiments, with good indication that Cox-Snell residuals approximated the unit exponential distribution (Supplementary Figure S3) (23) .
Accelerated Failure Time Model
Parametric AFT models were fit using a single 0-1 covariate to designate whether mice belonged to the rapamycin (covariate = 1) or control (covariate = 0) treatment (R package: survival; function: survreg) (23, 25) . Censoring information was incorporated into models when possible (19 of 29 experiments) . Quality of AFT model fits was assessed using QQ plots, residual analysis, measures of influence (df-betas), and comparison between observed and predicted survival curves (23, 25) . A basic AFT model assumption is that treatments have a multiplicative effect on survivorship percentiles, such that treatment effects can be described using the AFT model "deceleration factor" (23) . Validity of this assumption was assessed for each experiment using QQ plots, which provided good indication of multiplicative effects in most cases (r 2 > .80 for linear model in 28/29 experiments; Supplementary Figure S4 ). Unlike the Cox PH model, AFT models require specification of a survival time distribution (25) . For each experiment, the Akaike information criterion (AIC) was obtained after fitting AFT models using the Weibull, Gompertz, logistic, Gaussian, log-logistic, log-normal, or exponential distribution for survival times (23) . For nearly all experiments, the lowest AIC was provided by the Weibull or Gompertz distribution, and overall, similar deceleration factor estimates were obtained using either distribution (ie, mean difference of 1.24% among the 29 experiments). The Weibull distribution was therefore chosen as the survival time distribution to fit AFT models. Comparison between observed and predicted survival curves indicated that the Weibull AFT model provided satisfactory fit for each of the 29 experiments (Supplementary Figure S5) .
Number Needed to Treat
Number needed to treat (NNT) was estimated using the inverse of the absolute risk reduction (ARR), which is equal to the absolute survivorship difference between rapamycin (S R ) and control (S C ) treatments at age t (Equation 1) (27) . (27) .
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The 95% CI for NNT at a given age was estimated using the agespecific standard error (ie, ±1.96 × SE[NNT(t)]). The KolmogorovSmirnov test was applied to determine whether the lowest NNT value calculated across all ages was statistically significant (33) . This test is based upon the largest survivorship difference between treatments across the life span and thus provides a bidirectional test for significance of NNT or NNH (33).
Meta-Analysis Models
Log-transformed HRs were integrated across studies using a random effect inverse-variance meta-analysis model (R package: meta; function: metagen). This approach estimates summary statistics by assigning greater weight to HRs associated with lower standard error estimates. The HR was specified as the summary measure for metaanalysis (metagen option: sm = "HR"). The same random effects model was used to generate summary estimates for the proportion of mice in each experiment surviving beyond the pooled 90th percentile survival time, except relative risk was specified as the meta-analysis summary measure (metagen option: sm = "RR"). For NNT calculations, maximum ARR was estimated for each experiment and the random effects meta-analysis model was applied using the risk difference summary measure (metagen option: sm = "RD"). ARR summary estimates and CIs were inversed to obtain corresponding NNT estimates. AFT model integration across studies was achieved using megaanalysis (34), with survival times from all studies incorporated into the same AFT model (R package: survival; function: survreg). The mega-analysis AFT model included two covariates, with one nominal covariate indicating the source experiment for each survival time (29 levels), which was implemented with the "strata" specification to allow scale parameter estimates to vary among experiments. An additional 0-1 covariate term was included to indicate treatment group (0 = control; 1 = rapamycin), and the corresponding coefficient was used to estimate the AFT deceleration factor and evaluate effects of rapamycin on mouse survivorship. Rapamcycin effect size estimates were very similar using a Weibull or Gompertz megaanalysis model (0.4% difference). A Weibull mega-analysis model was therefore used, consistent with above analyses, and comparison between observed and predicted survival curves suggested good model specification (Supplementary Figure S6) . The Cox PH model was applied to survival times generated from 29 experimental studies in which effects of rapamycin were evaluated using WT inbred or hybrid mice (Table S1 ). Rapamycin decreased age-specific mortality significantly in 23 of 29 experiments (p < .05), with HR estimates ranging from 0.22 (95% CI: 0.06-0.82) to 0.92 (95% CI: 0.65-1.28). A summary HR of 0.51 (95% CI: 0.45-0.58) was estimated using a random effects inverse-variance weighted meta-analysis model (Figure 1 ). There was, however, significant heterogeneity among HR estimates (Q = 67.5, p < .0001), suggesting that HRs are influenced by factors varying among experiments. Forest plot inspection indicated that the seven lowest HR estimates were from experiments using female mice (HR ≤ 0.37), whereas the five highest HR estimates were from experiments using male mice (HR ≥ 0.71; Figure 1) . Consistent with this, pooled HRs calculated for each sex indicated that rapamycin decreased mortality rates more so in females (HR = 0.41; 95% CI: 0.35-0.48) as compared with males (HR = 0.63; 95% CI: 0.55-0.71; Figure 1) .
Results
Rapamycin
Meta-analysis of HR estimates was thus repeated for each sex separately (Figure 2 ). HR estimates among males and females individually were more consistent with only marginally significant heterogeneity (males: Q = 18.9, p = .124; females: Q = 21.2, p = .096). Male HR summary estimates did not differ significantly depending on genotype or time of treatment onset (Figure 2 ). In contrast, female HR summary estimates were slightly (not significantly) greater in experiments using pure inbred strains (HR = 0.50) as compared with those using HET3 F2 hybrids (HR = 0.39; Figure 2) . Experiments with females also showed stronger differences depending on time of treatment onset, with lower HR summary estimates in mice starting treatment at 9 months (HR = 0.41; 95% CI: 0.29-0.41) as compared with those starting at 19-20 months (HR = 0.52; 95% CI: 0.40-0.67).
Funnel Plot Asymmetry Consistent With Publication Bias Against Studies Demonstrating Less Favorable Effects of Rapamycin on Age-Specific Mortality
Meta-analysis accuracy is based on the premise that published experiments are representative of all existing data (published and unpublished) (35) . Funnel plot analysis was performed to address the validity of this assumption ( Figure 3A-C) (35) . Analysis of HR estimates from both sexes revealed significant funnel plot asymmetry (p = .022), consistent with publication bias against small sample size experiments generating higher HR estimates ( Figure 3A ). This trend was present with respect to both sexes, but was not significant with respect to either sex individually (p ≥ .25; Figure 3B and C).
Heterogeneity among the 29 HR estimates was further assessed by graphical approaches, including the L'Abbé, Galbraith, and Baujat plots ( Figure 3D-F) (36) . This indicated that at least 4 of 29 experiments could be considered statistical outliers (see Figure 3D -F). The 29 HR estimates were compared with those obtained previously in diabetic (db/db) mice (Supplementary Figure S7) (15) . Re-analysis of the db/db data set indicated that rapamycin increased mortality significantly in females (HR = 1.60; 95% CI: 1.02-2.52) but not in males (HR = 1.46; 95% CI: 0.91-2.33). L'Abbé, Galbraith, and Baujat plots definitively showed that db/db HR estimates are outliers relative to those from experiments utilizing WT mice (Supplementary Figure S7) .
Rapamycin Increases Survivorship by 13.0% (95% CI: 11.5-14.6%) With Stronger Increases in Females (15.1%) and Hybrid Genotypes (>14.4%)
The effects of rapamycin on survivorship were next evaluated using AFT modeling, which allows direct estimation of rapamycin's effect on survivorship, rather than the hazard function (25) . In all 29 experiments, rapamycin had a positive effect on survivorship, although the magnitude of survivorship increase varied from 3% to 40% (Figure 4) . The effect of rapamycin on survivorship was nonsignificant in 6 of 29 experiments (p > .05) that utilized male mice (Figure 4) .
To obtain pooled estimates, mega-analysis models were constructed (34) , with coefficients estimated from raw survival times combined across studies and included within the same AFT model. Among the 29 experiments, rapamycin increased survivorship significantly by 13.0% (95% CI: 11.5-14.6%; Figure 4 ). The increase was 15.1% in female mice (95% CI: 13.1-17.0%), but weaker in males (9.4% increased survivorship; 95% CI: 6.90-11.8%) with significant Sex × Treatment interaction (p = 3.92 × 10 -4 ; Figure 4 ). AFT model estimates differed depending on genotype. Rapamycin increased survivorship by 8.8% in pure inbred strains (ie, B6 or 129/ Sv mice; 95% CI: 6.2-11.6%), but significantly stronger increases were observed in other genotypes, which include HET3 F2 hybrid mice (95% CI: 12.5-16.3%) and inbred strains with mixed backgrounds (95% CI: 15.4-34.5%). Consistent with this, there was a significant interaction between rapamycin treatment and genotype (pure inbred vs other genotypes; p = .001).
These analyses were repeated for experiments involving each sex separately ( Figure 5 ). In both sexes, rapamycin increased survivorship more strongly in hybrid as compared with pure inbred strains, although this difference was more substantial in females ( Figure 5) . Notably, in males, the age at which rapamycin treatment was initiated did not impact its effect on survivorship ( Figure 5 ). However, in females, treatment started at 9 months of age increased survivorship by 18.1% (95% CI: 15.3-21.1%), whereas treatment started at 19 or 20 months of age increased survivorship by only 10.8% (95%: 7.8-14.0%; Figure 5 ).
Rapamycin-Treated Mice Are 3.97 (95% CI: 3.03-5.21) Times More Likely to Reach "Advanced Age" (90th Percentile of Pooled Survival Times)
Aging biologists have long argued that a treatment's effect on maximum life span is most meaningful with regard to its influence on fundamental aging mechanisms (37) . Experiments were therefore evaluated on whether rapamycin improved the rate at which mice survived to advanced age (defined as the 90th percentile of pooled survival times; Supplementary Figures S8 and S9) (37) . Among the 26 full-length experiments in which all mice died, rapamycin-treated mice were 1.51 to 26.6 times more likely than control mice to reach advanced age (Supplementary Figure S8) . Directionality of this trend was consistent among experiments but nonsignificant in eight cases (Supplementary Figure S8) . Summary estimates from these 26 experiments indicated that rapamycin-treated mice were 3.97 times as likely to reach advanced age (95% CI: 3.03-5.21). This effect was weaker in males as compared with females (2.98-vs 6.02-fold increase; Supplementary Figures S8 and S9) . Age of treatment onset did not significantly impact late-age survival for either sex, although in females, treatment onset at 19 or 20 months increased late-age survival less (3.85-fold increase) than treatment onset at 9 months (10.3-fold increase; Supplementary Figure S9 ).
Rapamycin Treatment Yields Maximal Survivorship
Benefit During Early Senescence With NNT of 3.10 (95% CI: 2.75-3.55)
Cox PH and AFT models estimate relative changes in the mortality/ survivorship of rapamycin-treated mice, but absolute change in survivorship may be more important for judging clinical value (26, 27) . NNT was therefore estimated for each experiment, based upon absolute survivorship differences between rapamycin-and controltreated mice ( Figure 6 ). For these analyses, minimum NNT across the life span is a convenient quantity, reflecting both NNT and age at which rapamycin treatment yields greatest survival benefit.
Minimum NNT ranged from 1.8 to 8.1 among the 29 experiments, suggesting that between 2 and 8 mice would require rapamycin treatment to yield one extra survivor (at the age of maximal benefit). Minimum NNT was significant with respect to 17 of 29 experiments (p < .05; Kolmogorov-Smirnov test; Figure 6 ). Summary estimates from all 29 experiments indicated a minimum NNT of 3.10 (95% CI: 2.75-3.55), although this value was significantly lower among females (NNT = 2.52; 95% CI: 2.27-2.84) as compared with males (NNT = 3.99; 95% CI: 3.41-4.80; Supplementary  Figures S10 and S11) .
After excluding three experiments terminated before all mice had died ( Figure 6A ), the average age of maximum rapamycin benefit was 27.3 months (±0.44) with treatment initiated at 2-4 months of age (n = 5 experiments), but this age increased to 33.5 months (±0.42) with treatment initiated at or after 9 months of age (n = 21 experiments; p = 8.96 × 10 -4 , two-sample t test). Age of maximum benefit, however, was always short of the pooled 90th percentile survival time (percentile range: 44.7-85.8; mean: 67.5 ± 2.13; Figure 6 ). NNT estimates were mapped to survivorship quantiles and integrated across all experiments (Supplementary Figure S12) . Based on meta-estimates, NNT minima were near the 70th percentile survival time, with a progressive increase beyond this time point, reaching 6.81 mice (95% CI: 5.87-8.10) at the 90th percentile survival time (Supplementary Figure S12) . Even if rapamycin treatment was initiated at 19 or 20 months, age of maximum benefit did not exceed the 70th percentile survival time (Supplementary Figure S12F) .
NNT provides a common scale for comparison between survival trends and pathology findings. To illustrate this, NNT was calculated for apparent causes of death assigned to rapamycin-treated and control mice of the HET3 hybrid genotype (Supplementary Figure S13) (3) . Rapamycin reduced mortality associated with lymphoma, hemangiosarcoma, and adrenal carcinoma, with NNT estimates of 6.9 (p = .117), 12. 
Excluded Experiments
Rapamycin increased survivorship by 10.9% on average in 56 excluded experiments (95% CI: 9.1-12.7 increase; AFT megaanalysis model; Supplementary Figure S15A) . Results from excluded experiments did not differ significantly between males (14.8% increase) and females (12.3% increase), although sex-specific associations were noted (Supplementary Figure S15) . In females, effects of rapamycin were weaker in inbred genotypes (compared with HET3 F2 hybrids) and mice that received rapamycin injections (rather than a dietary formulation; Supplementary Figures S15C) . In males, however, the opposite associations were observed (Supplementary Figure  S15B) . Additionally, in males (not females), there was marginal evidence to indicate that combined metformin + rapamycin treatment (29) 
Discussion
The course of aging research has been heavily influenced by rodent survival studies, which are challenging to perform, expensive, and require years to complete (38) . There is no substitute for experiments that are well designed, carefully executed, and well controlled, but even with this, sampling variation is unavoidable, and such variation is magnified by study-to-study differences in sex, genotype, and protocol (17) . Increasingly, moreover, the repeatability of experimental findings in all fields of medicine is being called into question (39, 40) . In mice, favorable effects of rapamycin on life span are not controversial, but experiments have yielded varying effect sizes and factors accounting for this variation are not fully understood. This study integrated findings from 29 experiments to identify factors contributing to such variation. The findings show that effect size variation associated with sex and genotype exceeds that expected from sampling alone, justifying further work to understand how these factors influence response to rapamycin treatment. This synthesis of evidence provides important context for interpreting future rapamycin experiments, which will likely be performed using additional mouse genotypes, but may also include other species (eg, rats, canines, and marmoset monkeys) (41, 42) .
Prior work has shown that treatments lengthening mouse life span can be genotype dependent (43) , which presents a challenge and dilemma for translational research (44) . Favorable effects of rapamycin on mouse life span have been heavily replicated, but there remain a large number of inbred mouse strains for which effects of rapamycin have not been studied (20) . So far, most experiments have been performed as part of the NIA's ITP, which utilizes HET3 F2 hybrids formed by crosses among the inbred strains Balb/cByJ, C57BL/6J, C3H/HeJ, and DBA/2 (2-6). Effects of rapamycin on HET3 life span, however, are not necessarily representative of the four parental strains, respectively. Findings from the current metaanalysis, for example, suggest attenuated effects of rapamycin in pure inbred strains, including the C57BL/6J genotype (Figure 4 ). This parallels previous data demonstrating less favorable effects of caloric restriction on the life span of inbred compared with hybrid mice (17) . Such genotype differences may be related to rapamycin metabolism and cellular uptake, since given the same dose (14 ppm), rapamycin blood levels are lower in B6 inbreds as compared with HET3 hybrids (14) . Potentially, such pharmacokinetic differences may be influenced by heterosis (hybrid vigor), which in mice and other species is known to enhance growth and growth-associated traits (45) (46) (47) . At the cellular level, this could promote mTOR activation in hybrid genotypes (48) , leading to especially favorable responses relative to pure inbred strains. Such hybridization effects may be important to consider for translation of findings to humans or other species with differing population structures.
Funnel plot analysis yielded trends consistent with publication bias against "low N" experiments demonstrating less favorable effects of rapamycin on life span ( Figures 3A and Supplementary  Figure S16) . Funnel plots are a graphical tool for identifying publication bias, based on an association between treatment effects and their standard errors (36) . It is difficult, however, to definitively establish such bias, particularly in the context of heterogeneity and small sample sizes (49, 50) . In this study, significant funnel plot asymmetry was detected with respect to HRs from all experiments including both sexes (n = 29 experiments; Figure 3A) , and similar trends were present with respect to each sex individually (n = 14 or 15 per sex; Figure 3B and C), as well as among experiments excluded from primary analyses ( Supplementary Figures S17A and S17B) . Essentially, these results demonstrate effect size differences between large N experiments as compared with low N experiments (35) . Large N experiments are more expensive, more time consuming, and more likely to be published regardless of outcome; indeed, this is exactly the NIA NTP's policy (1) . Low N experiments, on the other hand, are less expensive and may be done for exploratory purposes. If expected outcomes are not observed, findings from low N experiments may not reach publication stage, because the work may not be submitted or because journals resist publication of unexpected findings in the absence of strong statistical evidence (51) . In the current context, funnel plot asymmetry suggests that favorable effects of rapamycin on life span could be over-estimated by meta-analysis, due to omission of unpublished experiments. More definitive conclusions regarding publication bias, however, will be possible as future studies expand sample sizes available for meta-analysis.
NNT has not previously been used to quantify treatment effects in mouse survivorship experiments (26, 27) . As with hazard ratios and deceleration factors, NNT estimates from mouse experiments will not necessarily apply to humans, due to innate differences in human and mouse biology. However, because NNT is based on the absolute survivorship difference (26, 27) , it measures an alternative aspect of treatment effect that may not be captured by other metrics. Traditionally, aging biologists have focused on late-age survival trends, in line with the view that only treatments altering maximum life span can be understood to impact basic aging mechanisms (37) . Maximum life span, however, is de-emphasized by analysis of NNT, because NNT approaches infinity at late survival times, and in the current study, NNT minima were observed with surprising consistency during early senescence (≈70th percentile of pooled survival times; Figures 6 and Supplementary Figure S12 ). This shows that the greatest prophylactic value of rapamycin treatment may not be to extend maximum life span per se, but rather to prevent mortality during early senescence, leading to a more "rectangular" survival curve. A second advantage of NNT is that it can be calculated from both survival and necropsy data, providing a common scale for comparison of differences in group survivorship and lesion frequencies (eg, see Supplementary Figure S14 ).
